Melanotan II vs PT-141: Understanding the Difference

By NorthPeptide Research Team  |  April 12, 2026

Background: A Shared Origin

Both Melanotan II and PT-141 trace their lineage to alpha-melanocyte-stimulating hormone (α-MSH), a naturally occurring neuropeptide derived from pro-opiomelanocortin (POMC). In the 1980s, researchers at the University of Arizona began developing synthetic melanocortin analogs with the goal of producing a safe, effective tanning agent that would reduce UV-related skin damage. Their first major candidate was Melanotan I (afamelanotide) — a linear analog closely resembling natural α-MSH. Melanotan II followed as a more potent, cyclic, enzymatically resistant variant designed for improved receptor binding and metabolic stability.^[1]

The pro-sexual effect was found by accident, during pigmentation work. A single-blind, placebo-controlled pilot phase-I study of MTII in three male volunteers reported spontaneous penile erections lasting one to five hours after dosing, alongside the expected tanning.^[2] The Arizona group has since written up that discovery directly: MTII enhanced erectile activity in men and sexual desire and genital arousal in women, and the finding emerged while they were studying skin pigmentation.^[3] That observation pivoted the research direction and led to bremelanotide — developed under the code name PT-141 and marketed as Vyleesi — which is FDA-approved for acquired, generalized HSDD in premenopausal women (initial U.S. approval 2019).^[6]

Molecular Structure: One Atom-Level Difference

Melanotan II is a cyclic heptapeptide with the sequence Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂. The cyclic structure — created by a lactam bridge between Asp and Lys — dramatically increases its resistance to enzymatic degradation and extends its half-life compared to linear α-MSH analogs.

PT-141 (Bremelanotide) is not a shortened fragment of that molecule. It carries the same seven residues in the same Asp–Lys lactam ring: Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OH. The N-terminal acetyl-norleucine is present in both. The single structural difference is at the C-terminus — MTII ends in a carboxamide (–NH₂), PT-141 in a free carboxylic acid (–OH) — which makes bremelanotide the C-terminal deamidated form of MTII rather than a derived fragment. The molecular formulas differ by exactly that one change: C₅₀H₆₉N₁₅O₉ for MTII versus C₅₀H₆₈N₁₄O₁₀ for bremelanotide.

Receptor Pharmacology: Both Are Non-Selective

The melanocortin receptor system comprises five G-protein-coupled receptors (MC1R through MC5R), each with a distinct tissue distribution and physiological role:

• MC1R — Primarily expressed in melanocytes; governs pigmentation and UV-response pathways
• MC2R — Expressed in the adrenal cortex; binds ACTH exclusively; regulates cortisol synthesis
• MC3R — Expressed in the hypothalamus and limbic system; involved in energy homeostasis and feeding behavior
• MC4R — Widely distributed in the central nervous system; plays a central role in sexual function, appetite suppression, and erectile physiology
• MC5R — Expressed in exocrine glands; involved in sebaceous gland activity and immune modulation

Melanotan II is a non-selective agonist at MC1R, MC3R, MC4R, and MC5R. That broad binding profile accounts for its wide range of effects — and its broader side-effect burden. PT-141 is frequently described as MC4R-selective. It is not. Its FDA prescribing information states that bremelanotide "nonselectively activates several receptor subtypes with the following order of potency: MC1R, MC4R, MC3R, MC5R, MC2R" — MC1R first, not absent. The pro-sexual effect is attributed to MC3R/MC4R activation in the central nervous system,^[5] but MC1R activity is retained, and focal hyperpigmentation is a documented adverse reaction across the clinical development programme rather than an absent one.^[6] The practical difference between the two compounds is one of dose and cumulative exposure, not a clean receptor split.

Research Applications: Where the Paths Diverge

Melanotan II Research Applications

Because MTII activates multiple receptor subtypes simultaneously, its research applications span several physiological domains:

Skin pigmentation research: Via MC1R activation, MTII stimulates melanogenesis — the production of eumelanin (brown/black pigment) in melanocytes. In the pilot phase-I study, two of three volunteers showed increased pigmentation of the face, upper body and buttock — measured by quantitative reflectance as well as by visual assessment — a week after only five low subcutaneous doses.^[2] The programme's original rationale was photoprotection: a drug-induced tan as a route to lower UV-related skin damage.^[1]

Appetite and metabolism research: MC3R and MC4R activation by MTII suppresses food intake in animal models. Intracerebroventricular MTII inhibited feeding in four separate mouse models of hyperphagia — fasted C57BL/6J mice, ob/ob mice, agouti-yellow mice, and mice injected with neuropeptide Y — and the melanocortin antagonist SHU9119 completely blocked that inhibition. This is the experiment that established melanocortin neurons as a tonic brake on feeding behaviour, and it is why MTII remains a standard tool for probing central appetite regulation.^[7]

Sexual function research: MTII demonstrated centrally-mediated pro-erectile effects in human subjects years before PT-141 existed. In a double-blind, placebo-controlled crossover study of ten men with erectile dysfunction of no known organic cause, clinically apparent erections developed in eight of ten on MTII; mean duration of tip rigidity above 80% was 38.0 minutes on MTII versus 3.0 minutes on placebo (p=0.0045).^[8] The effect appears to be centrally mediated: in anaesthetized rats, melanotan-II induced erection when delivered directly into the paraventricular nucleus of the hypothalamus, acting there as a non-specific melanocortin agonist rather than through any one receptor subtype.^[14]

PT-141 / Bremelanotide Research Applications

HSDD and female sexual dysfunction: PT-141 is the only melanocortin receptor agonist the FDA has approved for a sexual-dysfunction indication — not the only approved melanocortin agonist outright; afamelanotide (Melanotan I) has been approved since 2019 for erythropoietic protoporphyria. Two identical randomized, double-blind, placebo-controlled phase 3 trials (the RECONNECT programme, 1,267 women randomized) met both coprimary endpoints: change from baseline in the Female Sexual Function Index desire-domain score (integrated studies 0.35, P<.001) and in Female Sexual Distress Scale–Desire/Arousal/Orgasm item 13 (integrated studies −0.33, P<.001).^[4] The number of satisfying sexual events was not a coprimary endpoint. The absolute effects are small, and an independent re-analysis of the same trial data reported that discontinuation due to adverse events was substantially higher on bremelanotide than on placebo — worth knowing before treating the approval as a strong efficacy signal.^[9]

Male erectile dysfunction research: Bremelanotide was developed for male ED first. In a double-blind, placebo-controlled phase 1 study, intranasal PT-141 produced a statistically significant erectile response versus placebo at doses above 7 mg, in healthy men and in Viagra-responsive ED patients, with first erection at roughly 30 minutes.^[10] The PDE5 non-responder finding comes from a separate subcutaneous crossover study in men who reported an adequate erection on 100 mg sildenafil no more than half the time; PT-141 produced a statistically significant erectile response at both 4 mg and 6 mg in that group, which is the basis for describing the mechanism as centrally mediated and distinct from peripheral vasodilation.^[11]

Inflammation and ischemia-reperfusion research: Melanocortin peptides are protective in experimental circulatory shock, myocardial ischemia, ischemic stroke, traumatic brain injury, and renal, intestinal and testicular ischemia, with the effect mediated largely by brain MC3R/MC4R.^[12] That body of work rests on α-MSH analogs such as NDP-α-MSH and on MC3R/MC4R-selective agonists — not on PT-141. Bremelanotide itself has not been characterized as a tool compound in ischemia-reperfusion models, and the melanocortin-class result should not be read as a PT-141 result.

Side Effect Profile: Driven by Dose, Not Receptors

The two compounds have overlapping receptor coverage, so the differences below are driven less by which receptors are hit than by dose, route and how often the compound is taken — MTII is typically used repeatedly and unsupervised for tanning, while bremelanotide is dosed episodically under a label that caps monthly use:

The Nevi Concern with Melanotan II

Perhaps the most significant safety signal specific to MTII is its effect on melanocytic nevi (moles). A review of the unregulated use of α-MSH analogs found an increasing number of case reports of melanocytic change in existing moles and newly emerging, sometimes dysplastic, nevi in melanotan I and II users, and four case reports describing melanoma arising from an existing mole during or shortly after melanotan use. The same review is explicit that conclusive evidence linking the two is lacking.^[13] Because MC1R activation stimulates melanocyte activity, the concern about malignant transformation is biologically plausible but has not been established causally in controlled studies. Nevus changes of this kind have not been reported for bremelanotide — but bremelanotide is not MC1R-inactive, and it does produce focal hyperpigmentation at sufficient cumulative exposure, so the honest reading of the difference is dose and duration of use, not receptor coverage.

Research Compound Availability at NorthPeptide

Both peptides are available for legitimate laboratory research purposes:

Which Peptide Is More Relevant to Your Research?

The answer depends entirely on the research question:

• Studying pigmentation pathways, UV response, or melanocyte biology? Melanotan II's MC1R activity makes it the appropriate tool compound.
• Studying central control of sexual function or appetite regulation? Either may be relevant. Both are non-selective, so neither isolates a single receptor; choose on dose, route and the depth of published data for the model you are running.
• Seeking the compound with the deepest human dataset? PT-141/Bremelanotide is far better characterized in human studies, with an FDA-approval dossier to reference. That is a difference in evidence base, not in receptor selectivity — both compounds are non-selective melanocortin agonists.

Related Articles

References

1. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930. (Historical review.) PubMed
2. Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777-1784. (Single-blind, placebo-controlled pilot phase-I study; n=3.) PubMed
3. Hadley ME. Discovery that a melanocortin regulates sexual functions in male and female humans. Peptides. 2005;26(10):1687-1689. (Narrative review.) PubMed
4. Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134(5):899-908. (Two identical randomized, double-blind, placebo-controlled phase 3 trials; 1,267 randomized.) PubMed
5. Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102. PubMed
6. Clayton AH, Kingsberg SA, Portman D, et al. Safety profile of bremelanotide across the clinical development program. J Womens Health (Larchmt). 2022;31(2):171-182. (Pooled safety review across phase 1–3 studies; 3,500 subjects, 43 completed studies.) PubMed
7. Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature. 1997;385(6612):165-168. (Preclinical; intracerebroventricular dosing in mice.) PubMed
8. Wessells H, Fuciarelli K, Hansen J, Hadley ME, Hruby VJ, Dorr R, Levine N. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol. 1998;160(2):389-393. (Double-blind, placebo-controlled crossover; n=10.) PubMed
9. Spielmans GI. Re-analyzing phase III bremelanotide trials for "hypoactive sexual desire disorder" in women. J Sex Res. 2021;58(9):1085-1105. (Independent meta-analysis / re-analysis of the RECONNECT trial data.) PubMed
10. Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004;16(1):51-59. (Randomized, double-blind, placebo-controlled phase 1.) PubMed
11. Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res. 2004;16(2):135-142. (Randomized phase 1/2, crossover in the ED cohort.) PubMed
12. Giuliani D, Minutoli L, Ottani A, et al. Melanocortins as potential therapeutic agents in severe hypoxic conditions. Front Neuroendocrinol. 2012;33(2):179-193. (Review of preclinical models.) PubMed
13. Habbema L, Halk AB, Neumann M, Bergman W. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. Int J Dermatol. 2017;56(10):975-980. (Narrative review of case reports; not a controlled study.) PubMed
14. Giuliano F, Clément P, Droupy S, Alexandre L, Bernabé J. Melanotan-II: investigation of the inducer and facilitator effects on penile erection in anaesthetized rat. Neuroscience. 2006;138(1):293-301. (Preclinical; intravenous and intra-paraventricular-nucleus dosing in rats.) PubMed

Regulatory statements about Vyleesi (bremelanotide) — the brand name and the 2019 initial U.S. approval, receptor potency order, contraindications, blood-pressure effect, focal hyperpigmentation rates, and the absence of a boxed warning — are taken from the current FDA prescribing information for VYLEESI, available via DailyMed.